Biologics Distributor for Orthopedic Practices in Louisville, KY

Vendor qualification for orthopedic accounts

Orthopedic practices and ambulatory surgery centers generally run new vendors through a credentialing step before any product reaches a shelf or a case cart. That step typically asks for the supplier's registration status, the donor eligibility framework the tissue was recovered under, and a certificate of analysis tied to the specific lot being purchased.

Precision Biologics treats this as a standing request rather than a one-time packet. Verified accounts can request a certificate of analysis, a donor eligibility summary, and a lot release record for any shipment, and can route those documents to a value analysis committee or purchasing office without delay.

NPI-verified accounts

Every account is opened against an NPI number, confirmed through the NPPES registry before the account is activated. This keeps ordering limited to licensed professionals and gives the practice a documented, repeatable onboarding step rather than an informal approval.

Cold chain and receiving in the region

Cryopreserved Wharton's jelly products are stored at -80 degrees C and shipped overnight on dry ice in validated containers, so a receiving process that checks container temperature and logs the lot number on arrival matters regardless of region. Louisville's position on common overnight carrier networks does not change this check; it is a standard step for any cryopreserved shipment.

Several of the catalog's formats, including the lyophilized Wharton's jelly product and the lyophilized exosome products, are shelf-stable and do not require a dry-ice receiving step. A practice that stocks both cryopreserved and shelf-stable formats should expect two different receiving procedures and plan storage space accordingly.

Documentation, state-board verification, and account setup

Whether a specific intended use of a Wharton's jelly product fits the homologous-use and minimal-manipulation criteria in 21 CFR 1271.10 is a determination for the practice and its own counsel, not something Precision Biologics advises on. Exosome products are not FDA-approved and are generally regulated as biologic drugs; purchasing and clinical-use decisions for those products belong to the ordering physician and their regulatory counsel.

A practice setting up an account should independently verify its physicians' standing with the Kentucky medical board and confirm its own compliance posture with legal counsel before placing an order. Precision Biologics supports this process with physician-level documentation calls that walk through certificates of analysis, donor eligibility summaries, and lot records, and with a straightforward NPI-based intake for new accounts.

FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.